Initial Management of Atrial Fibrillation in Pediatric Patients

Initial Assessment

The American College of Cardiology recommends performing a comprehensive evaluation, including medical history, symptom assessment, blood tests, and echocardiography, to identify potential triggers and structural abnormalities in pediatric patients with atrial fibrillation 1
Hemodynamic stability should be assessed immediately, as patients with hypotension, acute heart failure, or shock require emergent electrical cardioversion 2
A 12-lead ECG should be obtained to confirm atrial fibrillation and evaluate for signs of ischemia, pre-excitation, or structural abnormalities 2
Transthoracic echocardiography should be performed to assess ventricular function and identify structural heart disease 2

For hemodynamically stable pediatric patients with atrial fibrillation, rate control is the recommended initial approach, according to the American Heart Association 1, 3
Beta-blockers, diltiazem, verapamil, or digoxin are recommended as first-line medications for rate control in patients with preserved ventricular function (LVEF >40%) 1, 2
For patients with impaired ventricular function (LVEF ≤40%), beta-blockers and/or digoxin should be used, while avoiding non-dihydropyridine calcium channel blockers 1, 2

The American College of Cardiology recommends assessing stroke risk using appropriate risk stratification tools in pediatric patients with atrial fibrillation 1, 2
Anticoagulation is recommended for 3 to 4 weeks before and after cardioversion for patients with atrial fibrillation of unknown duration or that has lasted more than 48 hours 4
Direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists, except in patients with mechanical heart valves or mitral stenosis 2

Immediate electrical cardioversion should be performed in pediatric patients with hemodynamic instability due to atrial fibrillation 2
Pharmacological cardioversion may be considered in stable patients with symptomatic atrial fibrillation, using agents like flecainide, propafenone, or amiodarone 1, 3

Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) should be avoided in patients with ventricular dysfunction, as they can worsen heart failure 2
Anticoagulation should not be discontinued if sinus rhythm is restored, as the risk of thromboembolism persists 2
Detection of a delta wave on the surface ECG in a patient with atrial fibrillation requires EP study and ablation of the bypass tract, according to the American Heart Association 5